Drugs / Virus Specific T-cell (VST)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03475212 | Jun 2018 → Jun 2025 overdue | Epstein-Barr virus infection, adenoviridae infectious disease, cytomegalovirus infection | Pediatric Transplantation & Cellular Therapy Consortium | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Virus Specific T-cell (VST) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03475212 ↗ |
| Known as | VSTs | “The purpose of this study is to evaluate whether virus-specific T cell lines (VSTs) are safe and can effectively control three viruses (EBV, CMV, and adenovirus) in patients...” NCT03475212 ↗ |
| Modality | Cell therapy | “virus-specific T cell lines (VSTs)” NCT03475212 ↗ |